GREATER CHINA Strategy China And Hong Kong Property & Hong Kong Landlord Tariffs curtail US rate cuts, thereby hindering the recovery of Hong Kong property and tourism; Maintain OVERWEIGHT on China property. INDONESIA Strategy Alpha Picks: Outperform In Mar 25 Remove BBNI, BBRI, ASII, JSMR and KLBF; add BBCA, ICBP, ERAA and BUKA. MALAYSIA Update Pekat Group (PEKAT MK/BUY/RM1.08/Target: RM1.45) Good earnings visibility over 2025...
The selloff driven by the US’ unprecedented and perplexing tariff plans has liberated many investors of profits this year. Given the fluidity of market conditions, we highlight a number of domestic-focused stocks such as CENT, CD, DFI, HLA, PANU, PROP, RFMD, SSG and SIE as well as Singapore-focused REITS such as CDLHT, FEHT, FCT, KREIT, LREIT and PREIT. In addition, the MAS’ equity market review should inject much needed liquidity in 2H25. We lower our STI target to 3,720 (previously 4,115).
KEY HIGHLIGHTS Results Lendlease Global Commercial REIT (LREIT SP/BUY/S$0.53/Target: S$0.72) 1HFY25: Resilient contributions from Singapore; upside from office block at Jem. Singapore Exchange (SGX SP/HOLD/S$12.71/Target: S$12.58) 1HFY25: Record-high earnings driven by all business segments. Update Wilmar International (WIL SP/HOLD/S$3.26/Target: S$3.18) 4Q24 results preview: Better performance qoq, but lower yoy on lacklustre China operations and delayed sugar harvest. TRADERS' CORNER Seatr...
GREATER CHINA Strategy Small-Mid Cap Monthly: Countdown to Plover Bay’s 2024 results: Eyeing final dividend and 2025 outlook. Sector Automobile: Weekly: OEMs post upbeat January sales. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL, Fuyao and Desay. Update Aier Eye Hospital Group (300015 CH/HOLD/Rmb12.71/Target: Rmb13.80): Expecting slower growth amid weaker demand, yet outperforming peers. Downgrade to HOLD. INDONESIA Results XL Axiata (EXCL IJ/BUY/Rp2,290/Target: Rp3,300): 4Q24: NPAT jumps 93%...
For 1HFY25, SGX reported record-high revenue (+15.2% yoy) and adjusted PATMI (+27.3% yoy), driven by broad-based growth across all business segments. The cash equities and equity derivatives segments were clear outperformers on the back of higher SDAV and total traded volumes while the FICC segment continued its upward momentum. However, we opine that SGX is fairly valued at current price levels. Maintain HOLD but with a higher target price of S$12.58.
GREATER CHINA Economics Trade Export Growth Rebounded; Rush Order Ahead Of Tariffs? Sector Education Key growth themes in 2025 upon policy clarity and AI integration progress. Property Sales pull back mom before Chinese New Year; updates of 2024 op...
We expect SGX to report strong 1HFY25 revenue (+15% yoy) and adjusted PATMI (+16% yoy), driven by broad-based outperformance from most business segments. The cash equities and equity derivatives segments are poised to post strong results as trading value and volumes improve while the FICC segment is set to post record-high revenue driven by robust volumes. The ongoing stock market review is set to be completed in 2HFY25. We maintain HOLD with the same target price of S$11.83.
GREATER CHINA Update JD.com (9618 HK/BUY/HK$160.40/Target: HK$197.00): 3Q24 results preview: Promising outlook; benefitting from trade-in programme. INDONESIA Update Indosat (ISAT IJ/BUY/Rp2,490/Target: Rp3,100): Core earnings could jump 33% yoy in 2024; launches GPU Service for AI Computing. Maintain BUY. MALAYSIA Update Deleum (DLUM MK/HOLD/RM1.55/Target: RM1.70): Most of the share price outperformance is linked to P&M’s re-rating; we still see minor trading upside for upcoming MCM contracts...
For Sep 24, SGX reported strong operating statistics which saw SDAV reaching a two-year high, driven by increased market turnover value for China-linked SGX-listed companies. Total derivative traded volumes also surged to a four-year high, driven by the equity derivatives and commodities segments. However, with a lack of near-term catalysts, we still opine that SGX is fairly valued at current price levels. Maintain HOLD but with a higher PE-based target price of S$11.83 (S$11.62 previously).
GREATER CHINA Economics Economic Activity: August domestic activities remained weak, more demand-side measures are needed. Sector Banking: 1H24 results wrap-up: Walking a tightrope. Cement: Weekly: Unfavourable weather condition and tail-heavy LGSB issuance holding back cement demand. Construction: The momentum of FAI is yet to improve; awaiting policy supports in 2H24. Update Kuaishou (1024 HK/BUY/HK$38.15/Target: HK$70.00): Key takeaways from Kuaishou Investor Day 2024. SINGAPORE Update Singa...
For Aug 24, SGX reported that SDAV reached a two-year high, driven by increased market turnover value from both institutional and retail investors. Total derivative traded volumes were also higher, driven by the forex and commodities segments. With a lack of near-term catalysts, we opine that SGX is fairly valued at current price levels. Maintain HOLD but with a higher target price of S$11.62 (S$10.65 previously).
After Powell’s Jackson Hole speech on 23 August, we see a turning point starting with a US Fed rate cut in Sep 24 and lower rates heading into 2025. In the Singapore market, REITs and the property sector should benefit, as should highly-geared companies and those looking to recycle capital. Our current forecasts have incorporated lower NIMs for banks which we believe are protected by their high dividend yields.
KEY HIGHLIGHTS Results CapitaLand Ascendas REIT (CLAR SP/BUY/S$2.65/Target: S$3.44): 1H24: Backfilling vacant space at Changi Business Park. Singapore Exchange (SGX SP/HOLD/S$9.82/Target: S$10.65): FY24: Strong results in line as FICC outperforms. Thai Beverage (THBEV SP/BUY/S$0.50/Target:S$0.56): 9MFY24: Stable performance as beer outperforms. TRADERS’ CORNER Thai Beverage (THBEV SP): Trading BUY Venture Corp (VMS SP): Trading BUY
GREATER CHINA Economics Inflation Worrying fall in core CPI inflation. INDONESIA Results Kalbe Farma (KLBF IJ/HOLD/Rp1,665/Target: Rp1,700) 2Q24: Core NPAT rose 20.3% yoy; above expectations. MALAYSIA Update Gas Malaysia (GMB MK/HOLD/RM3.57/Target: RM3.50) Higher demand capacity to offset lower NG prices in 2024; stock offers attractive dividend ...
For FY24, SGX reported higher revenue (+3.1% yoy) and adjusted PATMI (+4.5% yoy), driven by the FICC and platform segments but offset by the cash equities and equities derivatives segments. With a lack of near-term catalysts, SGX is fairly valued at current price levels, in our view. Maintain HOLD but with a higher target price of S$10.65 (S$10.13 previously).
KEY HIGHLIGHTS Strategy The Impact Of Escalating Middle East Tensions A fluid situation with oil prices the key worry. Small/Mid Cap Highlights BRC Asia (BRC SP/BUY/S$1.94/Target: S$2.42) 1QFY24: Strong results as construction demand recovers. TRADERS’ CORNER Aztech Global (AZTECH SP): Trading BUY Isdn Holdings (ISDN SP): Trading BUY
GREATER CHINA Strategy Alpha Picks: February Conviction Calls We remain hedged, adding COSCO Shipping Holdings and Foxconn Industrial Internet to our BUY list, but include additional SELL calls on Li Auto and Xpeng. Sector Automobile: Weekly: EV sales remain lukewarm in the fourth week of 2024. Top SELLs: BYD, XPeng and Li Auto. Update Shenzhen Mindray Bio-Medical Electronics (300760 CH/BUY/Rmb273.19/Target: Rmb360.00): Acquires 21.12% stake in APT Medical; embracing tremendous business opportu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.